← All trials
NCT06492460
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 20, 2024
- Primary completion
- Sep 20, 2029
- Completion date
- Jul 17, 2033
- First posted
- Jul 9, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 422
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Guilin UniversityCollaborator
- Central South UniversityCollaborator
- Central South UniversityCollaborator
- Jiangsu Cancer Institute & HospitalCollaborator
- Sun Yat-Sen UniversityOfficial
- Sun Yat-Sen UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.